Leerink Swann Reiterates Outperform Rating for Kura Oncology Inc. (KURA)
Kura Oncology Inc. (NASDAQ:KURA)‘s stock had its “outperform” rating reaffirmed by analysts at Leerink Swann in a research note issued on Thursday. They presently have a $15.00 price target on the stock. Leerink Swann’s price objective points to a potential upside of 160.42% from the company’s current price.
KURA has been the topic of a number of other reports. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Wednesday, July 13th. Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Kura Oncology has an average rating of “Buy” and a consensus price target of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) traded up 2.86% during mid-day trading on Thursday, reaching $5.76. 25,535 shares of the company traded hands. The stock’s market capitalization is $107.96 million. The company’s 50 day moving average is $6.15 and its 200 day moving average is $4.19. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/kura-oncology-inc-kura-receives-new-coverage-from-analysts-at-leerink-swann.html
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities analysts forecast that Kura Oncology will post ($1.58) earnings per share for the current year.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC acquired a new position in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology at the end of the most recent reporting period. Institutional investors and hedge funds own 43.63% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.